Radioligand Therapies (RLTs)

#Affibody #Breast cancer #Radioligand Therapies (RLTs)

Affibody to reveal data from first-in-human cancer trial 

First-in-human data from a study into a radioligand therapy (RLT) targeting metastatic breast cancer is set to be announced.  Radiopharmaceutical company Affibody will present the data on ABY-271, the HER2-targeting RLT candidate, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting. The event will… Read More

#Cancer Research #News

#Actithera #Financing #Radioligand Therapies (RLTs) #Radiopharmaceuticals

Actithera raises $75.5m to support its precision radioligand therapies

Radiopharmaceutical biotech company Actithera has closed an oversubscribed $75.5 million Series A financing round.   The financing will support the advancement of Actithera’s lead fibroblast activation protein (FAP)-targeting asset into clinical development in multiple indications, while also enabling the continued development of its radioligand therapies (RLT) discovery platform… Read More

#Business & Investment #News

#Financing #Oncology #Radioligand Therapies (RLTs) #Radiopharmaceuticals #Starget Pharma #Start-ups

Starget secures $5.1m for clinical trial of targeted cancer therapy

Start-up Starget Pharma has raised $5.1 million in funding to support development of its radioligand-based therapies that target tumour cells with focused radiation. The investment was secured from Cancer Focus, a fund established in collaboration with the MD Anderson Cancer Center at the University of Texas. Read More

#Business & Investment #News #Start-up Zone

Cancer cells
#Cancer #Drug discovery #Oncology #Radioligand Therapies (RLTs)

How ready are we for radioligand therapies?  

DDW Editor Reece Armstrong speaks to Jasminka Taleska, Director, RLT HCS Readiness and Policy at Novartis, about the opportunities radioligand therapies (RLTs) represent in treating cancer patients.   RA: What are the potentials of RLTs across cancer?  JT: Cancer is an incredibly complex and… Read More

#Cancer Research #Exclusive Content